Search

Your search keyword '"Loretelli, C."' showing total 165 results
Start Over Author "Loretelli, C."
165 results on '"Loretelli, C."'

3. The immunological profile of SARS-CoV-2 infection in children is linked to clinical severity and age

Author

Vanetti, C., Lampasona, V., Stracuzzi, M., Fenizia, C., Biasin, M., Saulle, I., Limanaqi, F., Abdelsalam, A., Loretelli, C., Paradiso, L., Longoni, E., Barcellini, L., Piemonti, L., Marzinotto, I., Dispinseri, S., Amendola, A., Fappani, C., Tanzi, E., Clerici, M.S., Scarlatti, G., Zuccotti, G.V., Giacomet, V., and Trabattoni, D.

Subjects
Settore MED/04 - Patologia Generale, COVID-19, SARS-CoV-2 infection, children, immune response
Abstract

Coronavirus disease 19 (COVID-19) is clinically less severe in children, even if the large variety and degree of severity of symptoms reported in children pose a still unresolved challenge to clinicians. We performed an in-depth analysis of immunological profiles in 18 hospitalized SARS-CoV-2-infected children; results were compared to those obtained in 13 age- and sex-matched healthy controls (HC). Patients were categorized as paucisymptomatic/moderate (55.6%) or severe/critical (44.5%), according to established diagnostic criteria, and further stratified into infants (1–12 months, 39%), children (1–12 years, 44%), and adolescents (> 12 years, 17%). We assessed SARS-CoV-2-specific RBD antibodies (Ab), neutralizing antibodies (nAb) and circulating cytokines/chemokines in plasma; SARS-CoV-2-specific immune response was measured in peripheral blood mononuclear cells by gene expression and secretome analyses. Our results disclose peculiar circulating cytokine/chemokine profiles in patients sharing a similar clinical phenotype. A cluster of patients consisted of infants with severe symptoms who presented a hyperinflammatory profile, and extremely polarized antibody profiles, ranging from patients who were negative for Abs and nAbs to those who displayed very high levels of both. In a second cluster consisting of paucisymptomatic patients, a less pronounced increase of inflammatory cytokines along with an association between selected cytokines and humoral responses emerged. A third cluster still consisting of paucisymptomatic patients showed a circulating cytokine/chemokine profile which substantially overlapped with that of HC. SARS-CoV-2-stimulated production of pro-inflammatory proteins (IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-17, MIP-1β, and TNF-α), as well as T lymphocytes activation and migration-specific proteins were significantly increased in SARS-CoV-2 infected children compared to HC. Our findings suggest that immune response activation is directly correlated to clinical severity and to a lesser extent to age.

Published
2022
Full Text
View/download PDF

5. Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study (Targeted Oncology, (2020), 15, 1, (115-126), 10.1007/s11523-020-00698-x)

Author

Faloppi L., Puzzoni M., Casadei-Gardini A., Silvestris N., Masi G., Marisi G., Vivaldi C., Gadaleta C. D., Ziranu P., Bianconi M., Loretelli C., Demurtas L., Lai E., Giampieri R., Galizia E., Ulivi P., Battelli N., Falcone A., Cascinu S., Scartozzi M., Faloppi, L., Puzzoni, M., Casadei-Gardini, A., Silvestris, N., Masi, G., Marisi, G., Vivaldi, C., Gadaleta, C. D., Ziranu, P., Bianconi, M., Loretelli, C., Demurtas, L., Lai, E., Giampieri, R., Galizia, E., Ulivi, P., Battelli, N., Falcone, A., Cascinu, S., and Scartozzi, M.

Abstract

The listing of the author names and affiliations, which previously read.

Published
2020

9. P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab

Author

Puzzoni, M., primary, Demurtas, L., additional, Ziranu, P., additional, Lai, E., additional, Giampieri, R., additional, Faloppi, L., additional, Mandolesi, A., additional, Cremolini, C., additional, Masi, G., additional, Gelsomino, F., additional, Mariani, S., additional, Cubeddu, A., additional, Casula, L., additional, Liscia, N., additional, Pusceddu, V., additional, Antoniotti, C., additional, Loretelli, C., additional, Meriggi, F., additional, Zaniboni, A., additional, Falcone, A., additional, Cascinu, S., additional, and Scartozzi, M., additional

Published
2018
Full Text
View/download PDF

10. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab

Author

Puzzoni, M., primary, Demurtas, L., additional, Giampieri, R., additional, Ziranu, P., additional, Pusceddu, V., additional, Mandolesi, A., additional, Cremolini, C., additional, Masi, G., additional, Gelsomino, F., additional, Antoniotti, C., additional, Loretelli, C., additional, Meriggi, F., additional, Zaniboni, A., additional, Falcone, A., additional, Cascinu, S., additional, and Scartozzi, M., additional

Published
2017
Full Text
View/download PDF

11. Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)

Author

Scartozzi, M., primary, Giampieri, R., additional, Daniele, B., additional, Ferrari, D., additional, Lonardi, S., additional, Zaniboni, A., additional, Cavanna, L., additional, Rosati, G., additional, Pella, N., additional, Zampino, M.G., additional, Sozzi, P., additional, Casula, L., additional, Rota, S., additional, Germano, D., additional, Puzzoni, M., additional, Loretelli, C., additional, Zagonel, V., additional, Labianca, R., additional, Frontini, L., additional, and Cascinu, S., additional

Published
2016
Full Text
View/download PDF

12. Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)

Author

Giampieri, R., primary, Scartozzi, M., additional, Daniele, B., additional, Ferrari, D., additional, Lonardi, S., additional, Zaniboni, A., additional, Cavanna, L., additional, Rosati, G., additional, Pella, N., additional, Zampino, M.G., additional, Sozzi, P., additional, Casula, L., additional, Rota, S., additional, Germano, D., additional, Puzzoni, M., additional, Loretelli, C., additional, Zagonel, V., additional, Labianca, R., additional, Frontini, L., additional, and Cascinu, S., additional

Published
2016
Full Text
View/download PDF

13. P-209 - P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab

Author

Puzzoni, M., Demurtas, L., Ziranu, P., Lai, E., Giampieri, R., Faloppi, L., Mandolesi, A., Cremolini, C., Masi, G., Gelsomino, F., Mariani, S., Cubeddu, A., Casula, L., Liscia, N., Pusceddu, V., Antoniotti, C., Loretelli, C., Meriggi, F., Zaniboni, A., Falcone, A., Cascinu, S., and Scartozzi, M.

Published
2018
Full Text
View/download PDF

14. Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: combined analysis of VEGF and HIF-1a. Final results of the ALICE-2 study

Author

Faloppi, L., primary, Casadei Gardini, A., additional, Masi, G., additional, Silvestris, N., additional, Loretelli, C., additional, Ulivi, P., additional, Vivaldi, C., additional, Bianconi, M., additional, Giampieri, R., additional, Bittoni, A., additional, Andrikou, K., additional, Del Prete, M., additional, Gadaleta, C.D., additional, Scartozzi, M., additional, and Cascinu, S., additional

Published
2015
Full Text
View/download PDF

18. 539P - Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)

Author

Scartozzi, M., Giampieri, R., Daniele, B., Ferrari, D., Lonardi, S., Zaniboni, A., Cavanna, L., Rosati, G., Pella, N., Zampino, M.G., Sozzi, P., Casula, L., Rota, S., Germano, D., Puzzoni, M., Loretelli, C., Zagonel, V., Labianca, R., Frontini, L., and Cascinu, S.

Published
2016
Full Text
View/download PDF

19. D09 - Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)

Author

Giampieri, R., Scartozzi, M., Daniele, B., Ferrari, D., Lonardi, S., Zaniboni, A., Cavanna, L., Rosati, G., Pella, N., Zampino, M.G., Sozzi, P., Casula, L., Rota, S., Germano, D., Puzzoni, M., Loretelli, C., Zagonel, V., Labianca, R., Frontini, L., and Cascinu, S.

Published
2016
Full Text
View/download PDF

20. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

Author

Scartozzi, M, primary, Bianconi, M, additional, Faloppi, L, additional, Loretelli, C, additional, Bittoni, A, additional, Del Prete, M, additional, Giampieri, R, additional, Maccaroni, E, additional, Nicoletti, S, additional, Burattini, L, additional, Minardi, D, additional, Muzzonigro, G, additional, Montironi, R, additional, and Cascinu, S, additional

Published
2012
Full Text
View/download PDF

22. The Role of Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms in the Prediction of Clinical Outcome for advanced Hepatocellular Carcinoma Receiving Sorafenib

Author

Faloppi, L., primary, Scartozzi, M., additional, Baroni, G. Svegliati, additional, Loretelli, C., additional, De Minicis, S., additional, Mandolesi, A., additional, Bianconi, M., additional, Bearzi, I., additional, Benedetti, A., additional, and Cascinu, S., additional

Published
2012
Full Text
View/download PDF

24. Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms and Clinical Outcome in Advanced Renal Cell Carcinoma Patients Receiving First Line Sunitinib

Author

Bianconi, M., primary, Scartozzi, M., additional, Faloppi, L., additional, Loretelli, C., additional, Burattini, L., additional, Bittoni, A., additional, Del Prete, M., additional, Giampieri, R., additional, Montironi, R., additional, and Cascinu, S., additional

Published
2012
Full Text
View/download PDF

28. P.08.18 THE ROLE OF VEGF AND VEGFR POLYMORPHISMS IN THE PREDICTION OF CLINICAL OUTCOME FOR ADVANCED HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB

Author

Faloppi, L., primary, De Minicis, S., additional, Scartozzi, M., additional, Loretelli, C., additional, Mandolesi, A., additional, Biagetti, S., additional, Gemini, S., additional, Surace, G., additional, Bearzi, I., additional, Benedetti, A., additional, Cascinu, S., additional, and Svegliati-Baroni, G., additional

Published
2012
Full Text
View/download PDF

30. F-38 The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management

Author

Faloppi, L., primary, Scartozzi, M., additional, Baroni, G. Svegliati, additional, Bianconi, M., additional, De Minicis, S., additional, Giampieri, R., additional, Maccaroni, E., additional, Bittoni, A., additional, Del Prete, M., additional, Madolesi, A., additional, Loretelli, C., additional, Belvederesi, L., additional, Biagetti, S., additional, Bearzi, I., additional, Benedetti, A., additional, and Cascinu, S., additional

Published
2012
Full Text
View/download PDF

34. Tumor angiogenesis as predictive factor for site of relapse in patients with gastric cancer: Biological and clinical implications.

Author

Giampieri, R., primary, Scartozzi, M., additional, Loretelli, C., additional, Galizia, E., additional, Pistelli, M., additional, Bittoni, A., additional, Del Prete, M., additional, Mandolesi, A., additional, Siquini, W., additional, Berardi, R., additional, Trana, C., additional, Marmorale, C., additional, Fianchini, A., additional, Bearzi, I., additional, and Cascinu, S., additional

Published
2011
Full Text
View/download PDF

41. MSH2 splice site mutation and endometrial cancer

Author

Bianchi, F., primary, Rosati, S., additional, Belvederesi, L., additional, Loretelli, C., additional, Catalani, R., additional, Mandolesi, A., additional, Bracci, R., additional, Bearzi, I., additional, Porfiri, E., additional, and Cellerino, R., additional

Published
2006
Full Text
View/download PDF

45. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.

Author

Scartozzi, M, Bianconi, M, Faloppi, L, Loretelli, C, Bittoni, A, Del Prete, M, Giampieri, R, Maccaroni, E, Nicoletti, S, Burattini, L, Minardi, D, Muzzonigro, G, Montironi, R, and Cascinu, S

Subjects
RENAL cell carcinoma, GENETIC polymorphisms, MULTIVARIATE analysis, CYTOKINES, TUMORS, CELLULAR immunity
Abstract

Background:Currently, sunitinib represents one of the therapeutic strongholds for renal cell carcinoma, but the criteria for treatment selection are lacking. We assessed the role of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) polymorphisms in the prediction of the clinical outcome in metastatic renal cell carcinoma (mRCC) patients.Methods:A total of 84 tumour samples from mRCC patients receiving first-line sunitinib were tested for VEGF and VEGFR single-nucleotide polymorphisms (SNPs). The SNP results were correlated with progression-free survival (PFS) and overall survival (OS).Results:Median PFS was 8.22 months, although whereas median OS was 32.13 months. The VEGF A rs833061 resulted significant in PFS (17 vs 4 months; P<0.0001) and OS (38 vs 10 months; P<0.0001). The VEGF A rs699947 was significant for PFS (18 vs 4 months; P=0.0001) and OS (37 vs 16 months; P<0.0001). The VEGF A rs2010963 was significant in PFS (18 vs 8 vs 2 months; P=0.0001) and OS (31 vs 36 vs 9 months; P=0.0045). The VEGR3 rs6877011 was significant in PFS (12 vs 4 months; P=0.0075) and OS (36 vs 17 months; P=0.0001). At multivariate analysis, rs833061, rs2010963 and rs68877011 were significant in PFS, and rs833061 and rs68877011 were independent factors in OS.Conclusions:In our analysis, patients with TT polymorphism of rs833061, CC polymorphism of rs699947, CC polymorphism of rs2010963 and CG polymorphism of rs6877011 seem to have a worse PFS and OS when receiving first-line sunitinib. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results